'British approval' Astra Vaccine says it will be effective in mutation

<Anchor> The

AstraZeneca vaccine, which secured 10 million people in Korea, was approved for use in the UK yesterday (30th).

The immune effect is expected to be an average of 70% and a maximum of 80%, but the pharmaceutical company explained that it will have a similar effect against the mutant virus.

Reporter Park Chan-beom.

<Reporter> The

AstraZeneca vaccine, which has been approved by the UK government for the first time in the world, is expected to start on the 4th of next month.

The UK government says it has concluded that the AstraZeneca vaccine meets the approval criteria for safety, quality and efficiency.

The average immune effect was found to be 70.4%, and the effect appeared from the 22nd day after vaccination, and it was analyzed that the effect rose to a maximum of 80% if a total of 2 doses were taken at 3 months intervals.

AstraZeneca said the vaccine would have similar effects on the recently emerged mutant virus.

[Andrew Pollard/Oxford Vaccine Research Group Inspector: So far, there are no special concerns.

However, more clinical data are needed and will be available soon.] The

UK government-approved vaccination

regimen is

a common one with two doses.

Some analyzes showed that administration of only half of the dose at a single dose increased the effect to 90%, but it was explained that the clinical data were not sufficiently proven.

The UK government is hoping that the addition of the AstraZeneca vaccine, which is easier to store and transport than Pfizer or Modena, will speed up vaccination.

Following the UK, Argentina has also approved the use of the AstraZeneca vaccine.